Table 1.

Patient characteristics and detection of anti‐SARS‐CoV‐2 antibodies

Patient	Age	Sex	Symptoms at the time of Omicron BA.1 infection	Days post‐Omicron BA.1 infection	Previous infection	Time between Omicron BA.1 and non‐Omicron infection (days)	Neutralizing antibody titer	Abbott S anti‐S (BAU/ml)	Wantaï anti‐S (BAU/ml)	Roche anti‐S (BAU/ml)	Abbott N anti‐N (S/CO)
1	22	M	Mild	50	‐		128	2737.5	15000	7000	10.2
2	48	M	Mild	37	Sep‐2020	499	8	196.7	3774	1647	7.3
3	39	M	Mild	38	‐		8	<7.1	1.1	2.8	0.8
4	33	M	Asymptomatic	48	‐		32	47.1	87.9	105	6
5	50	F	Mild	45	‐		4	<7.1	0.6	7.7	6
6	40	F	Asymptomatic	40	‐		4	11.2	0.2	1.4	2.6
7	29	F	Mild	66	‐		8	55.4	6.0	44.6	4.5
8	35	M	Mild	42	Apr‐2021	282	32	1190.8	14184	7649	10.2
9	24	M	Mild	46	‐		8	21.8	2.8	27.4	3.8
10	23	M	Mild	43	Jul‐2021	198	8	242.2	4958	1618	3.6
11	28	M	Mild	45	‐		4	<7.1	0.03	<0.4	1.3
12	50	M	Mild	42	‐		4	<7.1	0.2	1.6	1.6
13	28	M	Mild	41	‐		32	487.9	11947	5001	8.4
14	22	F	Mild	37	Nov‐2020	454	32	1315.4	13505	6045	8.4
15	61	M	Mild	43	‐		4	<7.1	0.05	<0.4	2.9
16	35	F	Mild	42	‐		8	<7.1	0.5	1.7	3.9
17	48	M	Asymptomatic	45	‐		16	21.5	2.4	9.4	7.3
18	48	M	Mild	41	‐		4	8.9	1.1	3.3	2.2
19	45	M	Mild	43	‐		4	<7.1	1.7	5.2	2.5
20	40	F	Mild	40	May‐2021	250	32	455.3	5063	1893	3.9
21	35	F	Mild	48	‐		8	12.5	3.3	11.1	3.2
22	41	M	Asymptomatic	39	‐		4	<7.1	0.02	<0.4	2.0
23	30	M	Mild	32	‐		16	54	65.1	21.8	4.9
	Sensitivity (%)						100	65.2	69.6	86.9	91.3

Note: M, male; F, female; anti‐S, anti‐spike; anti‐N, anti‐nucleocapsid; S/CO, sample to cut‐off, according to the manufacturer's instructions positive result if S/CO ≥1.4.